SWI/SNF Complexes: Chromatin, Epigenetics and Cancer

Charles W. M. Roberts, M.D., Ph.D.
Associate Professor, Pediatric Oncology
Dana-Farber Cancer Institute, Children's Hospital and Harvard Medical School

Presented by GTC, a conference production company • (626) 256-6460 • www.gtcbio.com
SWI/SNF Complexes:
Chromatin, Epigenetics and Cancer

GTC
2nd Epigenetics in Drug Discovery meeting
Boston, MA  May 30, 2012

Charles W. M. Roberts M.D., Ph.D.
Dana-Farber Cancer Institute
Children’s Hospital
Harvard Medical School
Disclosure Information

• I receive funding and consulting fees from Novartis Institute for Biomedical Research via the Dana-Farber Cancer Institute-Novartis Drug Discovery Program.

• I will not discuss off label use and/or investigational use in my presentation.
SWI/SNF Complexes: Chromatin, Epigenetics and Cancer

GTC
2nd Epigenetics in Drug Discovery meeting
Boston, MA May 30, 2012

Charles W. M. Roberts M.D., Ph.D.
Dana-Farber Cancer Institute
Children’s Hospital
Harvard Medical School
Malignant Rhabdoid Tumor

• Highly aggressive cancer of early childhood
• Occurs in kidney, brain, and soft tissues
• Quite lethal cancer as large majority of children die of their disease, most within one year of diagnosis
• Familial cases consistent with ‘rhabdoid predisposition syndrome’
• Bi-allelic mutations in hSNF5/SMARCB1/INI1 are present in nearly all cases
SNF5/SMARCB1/INI1

- Identified as transcriptional activator in yeast
- Core member of the 2 MDa, 10-11 subunit, SWI/SNF chromatin-remodeling complex
- The SWI/SNF complex is highly evolutionarily conserved
ATTENTION!

The entire presentation is available to registered attendees only!

To view the rest of this exciting presentation and many more please register for the conference at

www.gtcbio.com

If you are already registered, please contact GTC for the full version.